Ipca Laboratories Ltd

3 published calls

• Emkay ResearchBUY17 Aug 2026

  1,7341,950+12.5%

  Ipca posted a broad-based sales beat across markets in 1QFY27, leading management to raise its FY27 consolidated topline growth and margin guidance, settling key investor debates and prompting an upward revision in the target price.

• PL CapitalBUY17 Aug 2026

  1,7342,000+15.3%

  IPCA reported a strong EBITDA beat of INR 6.4bn (up 50% YoY) and revised its FY27 revenue and margin guidance upwards. We maintain our Buy rating with a revised target price of INR 2,000/share, driven by API segment recovery, higher margins ex Unichem, and steady domestic formulation growth.

• BUY17 Aug 2026

  1,7342,060+18.8%

  Ipca Lab delivered a strong financial performance with an earnings beat driven by DF market share gains, robust exports, and improved operating leverage. We reiterate our BUY rating with a target price of INR2,060.

Ratings and target prices as published by each firm. Each summary condenses that firm's stated view in its own note and is attributed to it; no report text is reproduced.